AU2003288853A1 - Novel piperidine derivatives as modulators of chemokine receptor ccr5 - Google Patents

Novel piperidine derivatives as modulators of chemokine receptor ccr5

Info

Publication number
AU2003288853A1
AU2003288853A1 AU2003288853A AU2003288853A AU2003288853A1 AU 2003288853 A1 AU2003288853 A1 AU 2003288853A1 AU 2003288853 A AU2003288853 A AU 2003288853A AU 2003288853 A AU2003288853 A AU 2003288853A AU 2003288853 A1 AU2003288853 A1 AU 2003288853A1
Authority
AU
Australia
Prior art keywords
sup
modulators
chemokine receptor
piperidine derivatives
receptor ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003288853A
Other languages
English (en)
Inventor
John Oldfield
Howard Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003288853A1 publication Critical patent/AU2003288853A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003288853A 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5 Abandoned AU2003288853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0203820A SE0203820D0 (sv) 2002-12-20 2002-12-20 chemical compounds
SE0203820-6 2002-12-20
PCT/SE2003/002005 WO2004056808A1 (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5

Publications (1)

Publication Number Publication Date
AU2003288853A1 true AU2003288853A1 (en) 2004-07-14

Family

ID=20289969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003288853A Abandoned AU2003288853A1 (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5

Country Status (9)

Country Link
US (1) US20060069120A1 (enExample)
EP (1) EP1572683B1 (enExample)
JP (1) JP2006512364A (enExample)
AT (1) ATE342898T1 (enExample)
AU (1) AU2003288853A1 (enExample)
DE (1) DE60309206T2 (enExample)
ES (1) ES2274295T3 (enExample)
SE (1) SE0203820D0 (enExample)
WO (1) WO2004056808A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0301369D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
CN102131780A (zh) * 2008-09-01 2011-07-20 神经研究公司 适用于治疗包括抑郁症和惊恐障碍的中枢神经系统障碍的哌啶基丙酰胺衍生物
JP2012501307A (ja) * 2008-09-01 2012-01-19 ノイロサーチ アクティーゼルスカブ ピペリジン−４−アセトアミド誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのその使用
WO2011079007A1 (en) 2009-12-23 2011-06-30 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102241664B (zh) * 2010-05-13 2014-11-12 上海医药工业研究院 芳烷二胺类衍生物及其作为抗抑郁症药物的应用
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) * 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
EP1572683B1 (en) 2006-10-18
EP1572683A1 (en) 2005-09-14
ATE342898T1 (de) 2006-11-15
SE0203820D0 (sv) 2002-12-20
WO2004056808A8 (en) 2005-03-17
US20060069120A1 (en) 2006-03-30
DE60309206T2 (de) 2007-08-30
ES2274295T3 (es) 2007-05-16
WO2004056808A1 (en) 2004-07-08
DE60309206D1 (de) 2006-11-30
JP2006512364A (ja) 2006-04-13

Similar Documents

Publication Publication Date Title
MXPA02011304A (es) Derivados de piperidina farmaceuticamente activos, en partiular como moduladores de la actividad del receptor de la quimocina.
AU6461600A (en) Substituted piperidine compounds useful as modulators of chemokine receptor activity
MY137144A (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
WO2003042177A8 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
IL150201A0 (en) Novel piperidine and piperazine derivatives
TW200505856A (en) Chemical compounds
AU3850600A (en) Dalda analogs and their use
AU2003288853A1 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
WO2005101989A3 (en) Piperidine derivatives as modulators of chemokine receptor ccr5
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
ZA200110540B (en) Novel diphenyl-piperidine derivate.
WO2004056809A8 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
IL157653A0 (en) Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
AU5692500A (en) Piperazine derivatives as modulators of chemokine receptor activity
UA88303C2 (ru) Производные пиперидина, которые имеют активность по отношению к ccr5 (хемокинового рецептора 5)
SE0302090D0 (sv) Chemical compounds
SE0300104D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
TW200510307A (en) Chemical compounds
SE0403106D0 (sv) Chemical compounds
SE0303396D0 (sv) Chemical compounds
UA88002C2 (ru) Производной пиперидина как модуляторы рецептора ccr5 хемокина, способ их получения и фармацевтическая композиция на их основе
NO20053539L (no) Nye piperidinderivater som modulatorer for kjemokinreseptor CCR5.
AU1434201A (en) Antithrombotic agents
SE0301443D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase